Philadelphia chromosome

Also found in: Dictionary, Thesaurus, Medical, Financial, Acronyms, Wikipedia.

Philadelphia chromosome

[¦fil·ə¦del·fyə ′krō·mə‚skōp]

(pathology)

An abnormally small G-group chromosome found in the hematopoietic cells of most patients with chronic granulocytic leukemia.

References in periodicals archive ?

Among them, 187 (92.1%) patients were positive for BCR-ABL fusion gene by RT-PCR and Philadelphia chromosome on conventional cytogenetics (Figure-1).

Patterns of BCR/ABL Gene Rearrangements by Fluorescence in Situ Hybridization (FISH) in Chronic Myeloid Leukaemia

Table-III: Simple and complex variants of Philadelphia chromosome (n=12).

Cytogenetic and Molecular Analyses of Philadelphia Chromosome Variants in CML (Chronic Myeloid Leukemia) Patients from Sindh using Karyotyping and RT-PCR

Valenti et al., "Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications," Cancer Genetics and Cytogenetics, vol.

Imatinib mesylate effectiveness in chronic myeloid leukemia with additional cytogenetic abnormalities at diagnosis among Black Africans

Initial work-up Baseline laboratory investigations FBC + differential Urea and electrolytes, liver enzymes, serum LDH, serum urate Pregnancy test BM aspirate and trephine biopsy for: Morphology, including differential count to determine phase of disease Assessment of fibrosis Cytogenetic assessment on BM to determine: * % Philadelphia-positive cells (preferably 20 metaphases) * Presence of variant Philadelphia chromosome translocation * Presence of additional abnormalities, e.g.

Recommendations for the management of adult chronic myeloid leukaemia in South Africa

It is the first disorder for which the term "leukemia" was used; the first malignancy associated with a recurring chromosomal abnormality (Philadelphia chromosome); the first disease in which the chromosomal abnormality formed a fusion gene (BCR/ABL1 ); the first disease in which a protein fundamental to the pathogenesis of the disease was identified; and, the first disorder in which a therapeutic agent specifically targeted the molecular defect to effectively treat the disorder.

Myeloproliferative neoplasms: the role of molecular markers

Dasatinib and nilotinib, alternate ABL kinase inhibitors, restore hematologic and cytogenetic remission in the majority of patients with primary failure or acquired resistance in chronic-phase disease; in advanced disease and Philadelphia chromosome ALL, responses are more limited and relapse is common," Dr.

Novel drug targets imatinib-refractory leukemia: two studies suggest that nilotinib could provide an alternative for patients not benefiting from imatinib

Most people with CML have an abnormal chromosome, known as the Philadelphia chromosome, in which segments of chromosomes 9 and 22 are fused.

REVOLUTIONARY CANCER TREATMENT

The oncogenic activity arises from a translocation error between chromosomes 9 and 22; the abnormality of chromosome 22 is known as the Philadelphia chromosome.

Dramatic Results in Trial of New Leukemia Drug

Scientists have continued to hammer away at the so-called Philadelphia chromosome, a shortened chromosome 22.

New Drug Thwarts a Chronic Leukemia

The result is an assay that may be quicker, more sensitive, and more reproducible than previous RT-PCR-based assays for the Philadelphia chromosome (bcr/abl translocation) that use either cell lysates or isolated RNA.

Reducing the impact of endogenous ribonucleases on reverse transcription-PCR assay systems

prerequisite for participation in this contract is the approval for the following patent-free indication: a) treatment of adult patients with philadelphia chromosome positive (ph +) acute lymphoblastic leukemia (all) with resistance or intolerance to prior therapy.

Conclusion Of Indication-limited Non-exclusive Discount Agreements Pursuant To 130a (8) Sgb V On Medicines Containing The Active Substance Dasatinib -patents-free Indications- In The Context Of An Open-house Model

The discovery of the Philadelphia chromosome revolutionized the treatment of leukemia with the development of targeted tyrosine kinase inhibitors.